Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease: An Overview

George R. Bailie, PharmD, PhD, FCCP; Shaul G. Massry, MD


Pharmacotherapy. 2005;25(12):1687-1707. 

In This Article

Abstract and Introduction


The National Kidney Foundation developed and oversees the Kidney Disease Outcomes Quality Initiative, a process that develops clinical practice guidelines in nephrology. Recent guidelines address the aberrations in bone metabolism and disease that occur as a complication of chronic kidney disease. These guidelines provide, for the first time, a standard approach to the detection and management of alterations in calcium, phosphorus, and parathyroid hormone metabolism. The problems and sequelae of soft-tissue calcification are discussed, and recommendations are provided for reducing the associated morbidity and mortality.


The initial article in this series outlined the development of the Kidney Disease Outcomes Quality Initiative (K/DOQI),[1] a process initiated and overseen by the National Kidney Foundation. The second article reviewed salient points of the K/DOQI clinical practice guidelines for chronic kidney disease (CKD), by addressing the evaluation, classification, and stratification of CKD.[2] In the current article, we summarize those components of a further set of guidelines that are relevant to the practicing pharmacist—the K/DOQI clinical practice guidelines for bone metabolism and disease in CKD.[3]